Evidence map›Paper›PMID 34850851›Full record

ArticleBioscience reports2021

Commentary on: Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers.

Kexin Chen, Zhen Zeng, Chunxiang Ma, Yuan Dang, Hu Zhang

Open access · goldAbstract readComment
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Procedures of complementary medicine in rheumatology].Zeitschrift fur Rheumatologie · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kexin ChenDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Zhen ZengDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Chunxiang MaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Yuan DangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Hu ZhangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3281-4661
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal adenocarcinoma (COAD) is one subtype of colorectal carcinoma (CRC), whose development is associated with genetics, inappropriate immune response, and environmental factors. Although significant advances have been made in the treatment of COAD, the mortality rate remains high. It is a pressing need to explore novel therapeutic targets of COAD. Available evidence indicated that immune cell infiltration was correlated with cancer prognosis. To reveal the roles of immune cells in the COAD prognosis, a study published in Bioscience Reports by Li et al. (Bioscience Reports (2021) 41, https://doi.org/10.1042/BSR20203496) analyzed data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) dataset. It demonstrated a beneficial effect of Th17 cells in COAD prognosis. In addition, six hub genes (KRT23, ULBP2, ASRGL1, SERPINA1, SCIN, and SLC28A2) were identified to correlate with Th17 cells and COAD prognosis, suggesting one new therapy strategy and some predictive biomarkers of COAD. These findings reported by Li et al. may pave one way to explore the molecular mechanism of COAD further.

Indexed as

AdenocarcinomaColorectal NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, Tumorbiomarkercolorectal adenocarcinomaGene Expression OmnibusTh17 cellsThe Cancer Genome Atlas

Identifiers

PMID34850851
PMCPMC8685636
OpenAlexW3215061533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.